Quick Answer
DiaMedica Therapeutics Inc. reported Stockholders Equity of $56.11 million for the year ending 2025.
- DiaMedica Therapeutics Inc. showed an increase of +37.8% in Stockholders Equity from 2024 to 2025.
- This data is from DiaMedica Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $6.75 million | Q2 2018: $5.36 million | Q3 2018: $4.11 million | Q1 2019: $13.91 million | Q2 2019: $11.70 million | Q3 2019: $9.70 million | Q1 2020: $13.32 million | Q2 2020: $11.27 million | Q3 2020: $29.76 million | Q1 2021: $23.15 million | Q2 2021: $20.32 million | Q3 2021: $47.04 million | Q1 2022: $40.77 million | Q2 2022: $37.72 million | Q3 2022: $35.08 million | Q1 2023: $27.02 million | Q2 2023: $59.74 million | Q3 2023: $55.63 million | Q1 2024: $46.35 million | Q2 2024: $53.42 million | Q3 2024: $47.96 million | Q1 2025: $33.95 million | Q2 2025: $27.17 million | Q3 2025: $51.62 million.
- Over the full 10 years of available data (2016 to 2025), DiaMedica Therapeutics Inc.'s Stockholders Equity has grown by 4,950.5%.
- Historical annual values: Fiscal year 2025: $56.11 million | Fiscal year 2024: $40.72 million | Fiscal year 2023: $51.06 million | Fiscal year 2022: $31.83 million | Fiscal year 2021: $44.02 million | Fiscal year 2020: $26.01 million | Fiscal year 2019: $7.62 million | Fiscal year 2018: $17.03 million | Fiscal year 2017: $799.0 thousand | Fiscal year 2016: $1.11 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: